Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants

The COVID-19 pandemic continues to be a public health threat with emerging variants of SARS-CoV-2. Nirmatrelvir (PF-07321332) is a reversible, covalent inhibitor targeting the main protease (M(pro)) of SARS-CoV-2 and the active protease inhibitor in PAXLOVID (nirmatrelvir tablets and ritonavir table...

Descripción completa

Detalles Bibliográficos
Autores principales: Greasley, Samantha E., Noell, Stephen, Plotnikova, Olga, Ferre, RoseAnn, Liu, Wei, Bolanos, Ben, Fennell, Kimberly, Nicki, Jennifer, Craig, Tim, Zhu, Yuao, Stewart, Al E., Steppan, Claire M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Biochemistry and Molecular Biology 2022
Materias:
Accelerated Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023115/
https://www.ncbi.nlm.nih.gov/pubmed/35461811
http://dx.doi.org/10.1016/j.jbc.2022.101972

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023115/
https://www.ncbi.nlm.nih.gov/pubmed/35461811
http://dx.doi.org/10.1016/j.jbc.2022.101972

Ejemplares similares